

## [タイトル]

## From Protein Sciences to Therapeutics

## [日時・場所]

2024/7/26 (金)

10:00 - 11:00

ハイブリッドセミナー

・オンサイト：名古屋大学 ES 館 1 階 ES 会議室

・オンライン：Zoom

ID: 849 6278 7974

Passcode: 232447

## [プログラム]

10:00- 10:05 ご紹介

10:05- 10:45 演者：Dr. Matt Chu (Xyphos, Astellas US)

10:45- 11:00 総合討論



## [要旨]

Matt Chu is the Head of Protein Engineering at Xyphos, a cancer cell therapy unit in Astellas at South San Francisco CA, US, where he has built the Protein Engineering function enabling Design-Discovery-Production-Analysis capabilities to lead/support Cancer Cell Therapy & Tumor Microenvironment programs. He has also fostered collaboration with a number of Astellas groups including the Tsukuba Biologics Engineering, CMC-Research, Astellas Gene Therapy, Digital Transformation, as well as AI Drug-Discovery and Biologics Research. As a member of the Xyphos leadership team, Matt is helping shape both the science and culture on site in South San Francisco. Prior to Astellas, he worked at Tizona Therapeutics and Pfizer where he led a Protein Sciences team and contributed to CMC support/IND filing for antibody/cytokine programs, respectively. Matt completed his post-doctoral studies in structural biology at Stanford University then joined a Stanford spinoff, ConfometRx, working on GPCRs. He received his Ph.D. from University of Manchester, UK, following M.Phil. and undergraduate studies at The Chinese University of Hong Kong.

In this talk, Matt will present his scientific journey from UK, US to Japan, for his works in kinases, G-protein coupled receptors (GPCRs), cytokines and chimeric antigen receptor-T (CAR-T) cells.

